Device, system, and method for inhaling cannabis, nicotine, or medicinal compounds

Abstract

A particulate or vapor release and absorption technology for inhalation provides a formulation and / or process for cannabinoids, nicotine, lipid-soluble medications, and / or lipid-based medications, for permeation enhancing carriers that provide for effective absorption through inhalation. An inhalation system includes a body that has internal chambers. A top has holes therethrough for air flow from the internal chambers upon inhalation by a user. Cartridges are secured within the internal chambers. A formulation is contained within the cartridges that includes active ingredients. Particulates of the active ingredients are passively, non-combustibly released from the cartridges and entrained within the air flow upon the inhalation by the user. The particulates are sized for absorption into the bloodstream via lung tissue or nasal mucosa of the user. The active ingredients are cannabis, nicotine, and / or medicinal compounds.

Description

DEVICE, SYSTEM, AND METHOD FOR INHALING CANNABIS, NICOTINE, OR MEDICINAL COMPOUNDSFIELD OF THE INVENTION

[0001] The present invention relates generally to the field of inhalers and, more particularly, to a device, system, and method for inhaling cannabis, nicotine, and / or medicinal compounds. (Multiple pharmaceutical applications may have been found, and / or may yet be found, for this device, system, and / or method.)BACKGROUND OF THE INVENTION

[0002] Some of the most common cannabis consumption methods today may include inhalation of smokable products through combustion and / or a heated device for activation, which may include pre-rolled joints, pipes, and / or bongs. Likewise, some of the most common nicotine consumption methods today may still include inhalation of smokable products through combustion and / or a heated device for activation, which may include cigarettes.

[0003] The inhalation of cannabis and / or nicotine smoke from combusted and / or heated material is an ongoing safety concern, as there may be a heightened risk of adverse health effects which may occur as a result. Cannabis and / or nicotine consumers may benefit from a new, modernized method of consumption, which may deliver the same dosage and / or potency of smokable cannabis and / or nicotine, while preferably minimizing the adverse health risks related thereto.

[0004] Currently, non-smoking inhalable cannabis and / or nicotine options available to consumers may be limited, i.e., relative to the greater abundance of smokable options in the marketplace.

[0005] Combustible vaping devices, especially those integrating a portable battery system, are increasing in popularity. However, there may remain substantial health risks when using these devices, as consumers may still inhale byproducts from the device’s heating element, as well as from the cannabis and / or nicotine extract and / or from the cotton wick found within.

[0006] Historically, inhaled cannabinoids exhibit minimal or limited bioavailability, and / or health risks, through this administration pathway.

[0007] Alternative methods of cannabis consumption, like edibles and tinctures, may mitigate some of the adverse health risks associated with smoking cannabis products. However, this form of cannabis consumption may not provide consumers with the same satisfaction, bioavailability, and / or comfort that they might otherwise get when smoking or inhaling cannabis.

[0008] Apart from the above, widespread use of combustible vaping devices may pose a substantial risk to our ecology. Combustible vaping devices may be constructed of various plastic materials which, when disposed of, typically must be broken down over an extended period of time. An increase in popularity of disposable vaping devices as an alternative means of inhaling cannabis and / or nicotine products, notwithstanding the potentially adverse health risks associated with their use, may also cause substantial harm to the environment.

[0009] Previously, combustible vaping devices for consumption of cannabis, nicotine, and / or other substances may have caused one or more issues. In the prior art, combustible vaping devices for such substances may have exposed consumers to harmful smoke and chemicals. Perhaps, somewhat problematically, this in turn may have led to consumers to more frequently use disposable versions of combustible vaping devices, which may have led to an increase in harmful plastics entering landfills.

[0010] Prior art combustible vaping devices may have had little-to-no effect on reducing the strong scent associated with smoking cannabis. Use of these devices in public spaces may be undesired by other patrons, or even prohibited. Moreover, there may be legislation and / or policies whereby the U.S. Food and Drug Administration declines to approve “combustible” devices for any pharmaceutical applications.

[0011] Battery systems associated with prior art combustible vaping devices may leak over time, which may pose a substantial explosion risk to consumers during use.

[0012] It may be an object of the invention to provide a device, system, and / or method for inhaling cannabis or nicotine. It may be an object according to one aspect of the invention to provide an administration device, system, and / or method for inhaling cannabis, nicotine, or medicinal vapors, without the use of a direct heating element and / or a pressurized container. It may be an object according to one aspect of the invention to provide an administration device, system, and / or method for inhaling cannabis vapors containing monoterpenoids and / or terpenoids. It may be an object according to one aspect of the invention to provide a cannabis inhalation device made of ceramic material, plastic material, bioplastic material, compostable material, and / or another material. It may be an object of the invention to provide a small cylindrical plastic vessel for user convenience and / or portability. It may be an object of the invention to provide consumers with a discreet, effective, and / or convenient alternative to existing pharmaceutical options and / or to existing cannabis and / or nicotine consumption devices, systems, and / or methods.

[0013] It may be an object according to one aspect of the invention to provide a formulation of specially designed cannabinoids including THC, THCa, THCv, CBD, CBDa, D8 THC, CBG, CBN, terpenes, and flavonoids.

[0014] It may be an object according to one aspect of the invention to provide a passive aerosolization system and / or particulate release system utilizing monoterpenoids / terpenoids such as menthol, camphor, and / or tea tree oil, for the safe and effective delivery of cannabinoids and / or nicotine.

[0015] It may be an object of the invention to enhance cannabinoid and / or nicotine carriers, which may preferably aid in effective absorption through oral or nasal inhalation and / or intranasal administration. It may be an object of the invention to limit the size of inhaled particles to less than substantially about ten microns (10 pm) and, more preferably, about five microns (5 pm). And / or, it may be an object of the invention to provide a system, wherein some formulations utilize micro-emulsions.

[0016] It may be an object according to one aspect of the invention to employ emulsifying and / or dispersing agents, including but not limited to lecithin, sorbitan trioleate (Span 80), and / or Tween 85.

[0017] It may be an object of the invention to increase the bioavailability of inhaled cannabinoids and / or nicotine for efficient absorption and / or penetration into the pulmonary region and / or for efficient intranasal administration into the nasal region through the nasal mucosa. Nasal delivery may be alternately referred to herein as "intranasal administration" or "intranasal delivery." It may involve administering medications and / or substances through the nose, where they are absorbed into the bloodstream via the nasal mucosa. According to the invention, intranasal administration may be utilized for various purposes, including delivery of cannabis, nicotine, and / or medications such as nasal sprays for allergies, decongestants, hormone therapies, pain relief, and certain vaccines, and / or including essential oil wellness solutions. It may offer one or more advantages in comparison to prior art, potentially including (for example) rapid absorption, avoidance of first-pass metabolism in the liver, and / or ease of use, e.g., for patients who may otherwise have difficulty swallowing pills and / or may require quick onset of action. It may be an object according to one aspect of the invention to provide an effective and / or efficient dosing option, preferably through passive vapor and / or particulate inhalation.

[0018] It is an object of the present invention to obviate or mitigate one or more disadvantages and / or shortcomings associated with the prior art, to meet or provide for one or more needs and / or advantages, and / or to achieve one or more objects of the invention - one or more of which may preferably be readily appreciable by and / or suggested to those skilled in the art in view of the teachings and / or disclosures hereof.SUMMARY OF THE INVENTION

[0019] According to the invention, there is disclosed an inhalation system for passive, non-combustible inhalation and / or administration of cannabinoids, nicotine, and / or medicinal compounds. The inhalation system may preferably include a main vessel body, a top portion, one or more cartridges, and / or a formulation. The main vessel body may preferably have an inside portion which defines one or more internal chambers. Preferably, the top portion may securely engage the main vessel body, cover the internal chambers, and be shaped to define one or more inhalation holes therethrough, preferably for passage of an air flow from the internal chambers, preferably upon inhalation by a user. The cartridges may preferably be secured within the internal chambers. The formulation may preferably be contained within the cartridges. The formulation may preferably include one or more active ingredients. Particulates of the active ingredients may preferably be passively and / or non-combustibly released from the cartridges, and / or entrained within the aforesaid air flow, preferably upon the aforesaid inhalation by the user. The particulates may preferably be sized for absorption into the bloodstream via lung tissue and / or nasal mucosa of the user. The active ingredients may preferably be selected from the group consisting of cannabis, nicotine, and / or medicinal compounds.

[0020] According to an aspect of the invention, the formulation may preferably, but need not necessarily, include one or more terpenoids. The aforesaid release of the particulates from the cartridges may preferably, but need not necessarily, occur via passive aerosolization of the terpenoids. According to an aspect of the invention, the terpenoids may preferably, but need not necessarily, include one or more monoterpenoids. According to an aspect of the invention, the terpenoids may preferably, but need not necessarily, include one or more members selected from the group consisting of menthol, eucalyptol, camphor, and / or tea tree oil. According to an aspect of the invention, the terpenoids may preferably, but need not necessarily, be vasodilating and / or selected from the group consisting of beta caryophelle, linalool, alpha pinene, and / or myrcene. According to an aspect of the invention, the terpenoids may preferably, but need not necessarily, include one or more members selected from the group consisting of volatile carriers and / or permeation enhancers.

[0021] According to an aspect of the invention, the aforesaid one or more internal chambers may preferably, but need not necessarily, include two internal chambers. The aforesaid one or more cartridges may preferably, but need not necessarily, include two cartridges. Each of the cartridges may preferably, but need not necessarily, be secured within a respective one of the internal chambers. According to an aspect of the invention, the inhalation system may preferably, but need not necessarily, include a switch that is manually actuable by the user to select one of the cartridges for active use.

[0022] According to an aspect of the invention, the main vessel body may preferably, but need not necessarily, be reusable and / or constructed from one or more ceramic materials. Or, according to another aspect of the invention, the main vessel body may preferably, but need not necessarily, be disposable and / or constructed from one or more plastic materials.

[0023] According to an aspect of the invention, the top portion may preferably, but need not necessarily, be rounded to sealably conform with the shape of a mouth and / or nostril of the user. According to another aspect of the invention, the top portion may preferably, but need not necessarily, include a nose- / mouthpiece to sealably conform with the shape of a nostril and / or mouth of the user. According to an aspect of the invention, the nose- / mouthpiece may preferably, but need not necessarily, be constructed from a silicone material.

[0024] According to an aspect of the invention, the top portion may preferably, but need not necessarily, be selectively twistable to move the inhalation holes between (i) a closed configuration which may preferably, but need not necessarily, block the inhalation holes in the top portion against said air flow, and preferably thus limit the aforesaid passive release of the particulates, and / or (ii) an open configuration which may preferably, but need not necessarily, permit said air flow and / or the aforesaid passive release of the particulates.

[0025] According to an aspect of the invention, the inhalation system may preferably, but need not necessarily, include a selectively removable top cap that preferably (i) securely engages the top portion and / or blocks the inhalation holes in the top portion against said air flow, preferably thus limiting the aforesaid passive release of the particulates, and / or (ii) when removed, permits said air flow and / or the aforesaid passive release of the particulates.

[0026] According to an aspect of the invention, the top portion may preferably, but need not necessarily, have a fishhook rim that snaps onto the main vessel body.

[0027] According to an aspect of the invention, the cartridges may preferably, but need not necessarily, be wick cartridges. According to an aspect of the invention, each of the wick cartridges may preferably, but need not necessarily, hold about 1 to 20 mL of the formulation. According to an aspect of the invention, each of the wick cartridges may preferably, but need not necessarily, hold a formulation density of about 0.02 to 0.31 g / cubic centimeter ± about 10%. According to an aspect of the invention, the wick cartridges may preferably, but need not necessarily, be constructed from a cotton material.

[0028] According to an aspect of the invention, the inhalation system may preferably, but need not necessarily, include an activation button that preferably may be selectively actuable to heat the internal chambers and / or the cartridges, and / or to permit the aforesaid passage of the aforesaid air flow, preferably from the internal chambers, out through the inhalation holes, and / or upon inhalation by the user. The inhalation system may preferably, but need not necessarily, include oneor more flow cut-off members that may preferably block the aforesaid passage of the aforesaid air flow, preferably from the internal chambers, preferably when the activation button is not actuated.

[0029] According to an aspect of the invention, the inhalation system may preferably, but need not necessarily, include top and / or bottom clamper devices, preferably within the internal chambers. The top and / or bottom clamper devices may preferably, but need not necessarily, secure the cartridges within the internal chambers.

[0030] According to an aspect of the invention, the inhalation system may preferably, but need not necessarily, include a one-way valve to permit the aforesaid air flow, preferably over the cartridges and / or out through the inhalation holes in the top portion, preferably upon inhalation by the user, and / or to otherwise restrict the aforesaid air flow. According to an aspect of the invention, the one-way valve may preferably, but need not necessarily, be closed at all times other than upon inhalation by the user.

[0031] According to an aspect of the invention, each of the particulates may preferably, but need not necessarily, have a size of less than about ten microns (10 pm). According to an aspect of the invention, each of the particulates may preferably, but need not necessarily, have a size of less than about five microns (5 pm).

[0032] According to an aspect of the invention, the formulation may preferably, but need not necessarily, include one or more emulsifying and / or dispersing agents.

[0033] According to an aspect of the invention, the inhalation system may preferably, but need not necessarily, include a bottom portion that may preferably securely engage the main vessel body, cover the internal chambers, and / or be shaped to define one or more ventilation holes therethrough, preferably for passage of the air flow into the internal chambers, preferably upon inhalation by the user.

[0034] According to an aspect of the invention, the active ingredients may preferably, but need not necessarily, include one or more members selected from the group consisting of THC, THCa, THCv, CBD, CBDa, D8 THC, CBG, and / or CBN. The formulation may preferably, but need not necessarily, include one or more terpenes and / or flavonoids.

[0035] According to an aspect of the invention, the main vessel body may preferably, but need not necessarily, be pocket-sized for user convenience and / or portability.

[0036] According to the invention, there is also disclosed a cannabinoid formulation, preferably for non-combustible inhalation. The cannabinoid formulation may preferably, but need not necessarily, include one or more cannabinoids, one or more emulsifying and / or dispersing agents, and / or a volatile carrier oil. The cannabinoids may preferably, but need not necessarily, be selected from the group consisting of THC, THCa, THCv, CBD, CBDa, D8 THC, CBG, and / or CBN. The emulsifying and / or dispersing agents may preferably, but need not necessarily, be selected from thegroup consisting of lecithin, sorbitan trioleate, Span 80, and / or Tween 85. The volatile carrier oil may preferably, but need not necessarily, include menthol and / or another monoterpenoid.

[0037] According to an aspect of the invention, the cannabinoids may preferably, but need not necessarily, be an appropriate size to enter the bloodstream via nasal mucosa and / or for absorption in lung tissue. According to an aspect of the invention, the emulsifying and / or dispersing agents may preferably, but need not necessarily, achieve particle sizes less than about ten microns (10 pm). According to an aspect of the invention, the emulsifying and / or dispersing agents may preferably, but need not necessarily, achieve particle sizes less than about five microns (5 pm).

[0038] According to the invention, there is also disclosed a device, system, and / or method for inhaling cannabis and / or nicotine. Preferably, the device and / or system includes a small cylindrical plastic vessel, similar in dimension to a tube of chapstick. Preferably, the vessel is perforated with small holes for air flow. The small holes may preferably be provided at a top portion of the device. According to the invention, the top portion of the device may preferably, but need not necessarily, be rounded - preferably, but not necessarily, to enable, improve, and / or optimize its use during inhalation.

[0039] According to an aspect of the invention, the device, system, and / or method may preferably, but need not necessarily, include one or more specially-formulated cannabinoids, nicotine, or medicinal components for use in the vessel. Cannabinoid formulations according to the invention may include numerous cannabinoids, terpenes, and / or flavonoids. The cannabinoid formulations may preferably, but need not necessarily, include (among other things) one or more of the following: THC, THCa, THCv, CBD, CBDa, D8 THC, CBG, and / or CBN.

[0040] According to an aspect of the invention, the device, system, and / or method may preferably, but need not necessarily, utilize passive aerosolization of monoterpenoids and / or terpenoids, and / or passive release of particulates. The monoterpenoids and / or terpenoids may preferably, but need not necessarily, include (among other things) menthol, camphor, and / or tea tree oil. The monoterpenoids and / or terpenoids may preferably, but need not necessarily, safely and / or efficaciously carry and / or deliver cannabinoids, nicotine, and / or other drugs. According to the invention, the device, system, and / or method may preferably, but need not necessarily, include cannabinoids, nicotine, and / or others drugs which are broken-down to an appropriate size to enable absorption in the lung tissue and / or to enable delivery through the nose (where they can be absorbed into the bloodstream via the nasal mucosa). That said, they may or may not be so broken-down, or reduced in size. According to the invention, some formulations may be effective without being micro-particulates. For example, some terpene-only or nicotine formulations may be effective without being micro-particulates, although micro-emulsions thereof may improve their bioavailability.

[0041] According to an aspect of the invention, the device, system, and / or method may preferably, but need not necessarily, utilize a formulation of cannabinoids and / or nicotine specifically adapted for inhalation. The formulation may preferably, but need not necessarily, include cannabinoids, nicotine, and / or medicinal compounds with particle sizes of under substantially about ten microns (10 pm) and, preferably, about five microns (5 pm). The formulation may preferably, but need not necessarily, include one or more emulsifying and / or dispersing agents. The emulsifying and / or dispersing agents may preferably, but need not necessarily, including lecithin, sorbitan trioleate (e.g., Span 80), and / or Tween 85. The cannabis and / or nicotine solution may preferably, but need not necessarily, be dispersed in a carrier oil, for example, a monoterpenoid such as menthol. The oil solution may preferably, but need not necessarily, be packaged in small cylindrical plastic tubes. The tubes may preferably, but need not necessarily, have small airflow holes at the top. The tubes may preferably, but need not necessarily, be fitted with a snap-on cap. The snap-on cap may preferably, but need not necessarily, help slow and / or stop evaporation of the solution and / or its active ingredients, for example, when the product is not in use.

[0042] According to an aspect of the invention, preferably during the use of the product, users may preferably (but need not necessarily) open the vessel cap, press the top portion gently to the nostril to create a seal, and / or inhale. Preferably, after the user inhales a desired amount, the user may preferably close the cap of the vessel.

[0043] There may be one or more biological barriers encountered in nasal and / or pulmonary administration of cannabinoids and / or nicotine. These barriers may include: (A) a surfactant layer or mucus layer; (B) an epithelial layer; (C) an interstitium and / or basement membrane; and / or (D) a capillary endothelium. Cannabinoids on their own may have little or no bioavailability through one or more of these administration pathways. According to an aspect of the invention, the device, system, and / or method may preferably, but need not necessarily, utilize processing, a process, and / or a formulation which enables the cannabinoids to become bio-available for absorption and / or penetration in the pulmonary region. According to the invention, the device, system, and / or method may preferably, but need not necessarily, provide an efficient and / or effective dosing option, preferably through passive vapor inhalation and / or passive particulate release.

[0044] Preferably, the device, system, and / or method may help increase convenience and / or reduce risks associated with cannabis inhalation devices, e.g., as compared with prior art cannabis and / or nicotine inhalation devices. The device, system, and / or method may preferably, but need not necessarily, help (a) reduce the amount of harmful combustibles entering the body, (b) increase safety and / or security of using a cannabis and / or nicotine inhalation device, and / or (c) increase convenience of carrying and / or using a cannabis and / or nicotine inhalation device.

[0045] According to an aspect of the invention, the device may preferably, but need not necessarily, help avoid, minimize, and / or reduce an amount of harmful combustibles otherwise entering the body when using a cannabis and / or nicotine inhalation device.

[0046] According to an aspect of the invention, the top of the device may preferably, but need not necessarily, be rounded. The device, system, and / or method may preferably, but need not necessarily, use the rounded top of the device to form a seal between the device and a nostril.

[0047] According to an aspect of the invention, the device may preferably, but need not necessarily, help eliminate, minimize, and / or reduce any odour and / or scent otherwise associated with the use of a cannabis and / or nicotine inhalation device.

[0048] Persons skilled in the art will appreciate in view of the teachings and disclosures herein that the cannabis and / or nicotine inhalation device, system, and / or method, according to the invention, may offer significant advantageous utilities and / or functionality in comparison to the prior art.

[0049] Other advantages, features, and / or characteristics of the present invention, as well as methods of operation and functions of the related elements of the structure, operation, and / or the combination of parts, features, and / or economies of manufacture, will become more apparent upon consideration of the detailed description with reference to the figures which accompany this application.BRIEF DESCRIPTION OF THE DRAWINGS

[0050] The novel features which are believed to be characteristic of the present invention, and related devices, systems, and / or methods according to the present invention, as to their structure, organization, use, and / or methods of manufacture and / or operation, together with further objectives and advantages thereof, may be better understood from the figures which accompany this application, in which presently preferred embodiments of the invention have been illustrated by way of example. It is expressly understood, however, that such figures have been provided for the purpose of illustration and / or description only, and not intended as a definition of the limits of the invention. In the accompanying drawings:

[0051] FIG. 1 is a left side elevational view of a device according to a preferred embodiment of the invention;

[0052] FIG. 2 is a right side elevational view of the device of FIG. 1;

[0053] FIG. 3 is a partially sectional view of the device of FIG. 1;

[0054] FIG. 4 is a disassembled side elevational view of the device of FIG. 1;

[0055] FIG. 5 is a bottom plan view of the device of FIG. 1;

[0056] FIG. 6 is a top plan view of the device of FIG. 1;

[0057] FIG. 7 is a partially sectional view of the device of FIG. 1, shown without a wick cartridge;

[0058] FIG. 8 is a side elevational view of the wick cartridge of the device of FIG. 1;

[0059] FIG. 9 is side sectional view of a main vessel body of FIG. 14;

[0060] FIG. 10 is a top plan view of the main vessel body of FIG. 9;

[0061] FIG. 11 is a disassembled side elevational view of a device according to another preferred embodiment of the invention;

[0062] FIG. 12 is a side elevational view of a device according to another preferred embodiment of the invention;

[0063] FIG. 13 is a disassembled side elevational view of the device of FIG. 12;

[0064] FIG. 14 is a partially sectional view of the main vessel body of the device of FIG. 12;

[0065] FIG. 15 is a disassembled side elevational view of a device according to another preferred embodiment of the invention;

[0066] FIG. 16 is an assembled side elevational view of the device of FIG. 15;

[0067] FIG. 17 is a partially assembled and partially sectional view of the device of FIG. 15;

[0068] FIG. 18 is a partially assembled side elevational view of the device of FIG. 15, shown without a main vessel body;

[0069] FIG. 19 is a disassembled side elevational view of a device according to another preferred embodiment of the invention;

[0070] FIG. 20 is a disassembled side elevational view of a device according to another preferred embodiment of the invention;

[0071] FIG. 21 is a disassembled side elevational view of a device according to another preferred embodiment of the invention;

[0072] FIG. 22 is a partially disassembled side elevational view of a device according to another preferred embodiment of the invention;

[0073] FIG. 23 is a top plan view of a switch component of the device of FIG. 22;

[0074] FIG. 24 is a sectional side view of a bottom portion and spring of the device of FIG. 22;

[0075] FIG. 25 is a disassembled side view of chambers and cartridges of the device of FIG. 22;

[0076] FIG. 26 is a side view of a chamber component of FIG. 25;

[0077] FIG. 27 is a front view of another chamber component of FIG. 25;

[0078] FIG. 28 is a partially assembled side view of the chambers and cartridges of FIG. 25;

[0079] FIG. 29 is a side elevational view of a device according to another preferred embodiment of the invention;

[0080] FIG. 30 is a side elevational view of a device according to another preferred embodiment of the invention;

[0081] FIG. 31 is a disassembled, partially sectional side view of the device of FIG. 29;

[0082] FIG. 32 is a partially sectional side view of a chamber of the device of FIG. 29;

[0083] FIG. 33 is a disassembled, partially sectional side view of the device of FIG. 30;

[0084] FIG. 34 is a partially sectional side view of a chamber of the device of FIG. 30;

[0085] FIG. 35 is a sectional side view of another component of the device of FIG. 30;

[0086] FIG. 36 is a perspective view of a wick cartridge according to another preferred embodiment of the invention;

[0087] FIG. 37 is a perspective view of the wick cartridge of FIG. 8;

[0088] FIG. 38 is a perspective view of another wick cartridge according to another preferred embodiment of the invention; and

[0089] FIG. 39 is a disassembled side elevational view of a device according to another preferred embodiment of the invention.DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

[0090] This disclosure, including the accompanying figures, may include or reference one or more dimensions, numbers, materials of construction, words, phrases, sentences, arrangements, and / or configurations which may be included by way of example. It may bear repeating, in this respect specifically, that such figures and / or any such aspects of this disclosure are for the purpose of illustration and description only, and not intended as a definition of the limits of the invention.

[0091] With reference to accompanying FIGS. 1 to 39, there are shown various embodiments of a cannabis, nicotine, and / or medicinal compound inhalation device, system, and / or method (alternately herein, the “inhalation device” or the “inhalation system”) 50 according to a preferred embodiment of the invention. In FIGS. 1-4, 6-7, 11-13, 15-18, 20-22, 29-31, 33, and 39, the inhalation system 50 is adapted for use by consumers through inhaling through a single mouthpiece 76. The system 50 includes a main body 60 with space for one chamber 64 or two chambers 64a, 64b, each holding a wick cartridge 80 or wick cartridge (carrier vessel) components 80a, 80b. The system 50 also includes a top portion 70, with a silicone nasal or mouthpiece 76 fit tightly into the top portion 70, as well as a bottom portion 130 with two ventilation holes 132 at its bottom. The inside portion 62 of the main body 60 has a chamber compartment 64 holding a wick and cartridge component 80 (as perhaps best seen in FIG. 3) or two chamber compartments 64a, 64b within it, each holding a wick and cartridge component 80a, 80b (as perhaps best seen in FIG. 15). As described in further detail elsewhere herein, these wick cartridge components 80, 80a, 80b aresized, shaped, and / or otherwise adapted to securely engage with the interior chambers 64, 64a, 64b of the inhalation device and / or system 50.

[0092] One or more one-way valves 120 may preferably prevent the chambers 64a, 64b from leaking.

[0093] The diameter and / or gauge of the material is preferably suited to withstand common grip pressure during use.

[0094] The inhalation device and / or system 50 is preferably sized and adapted to span a total length of substantially about 69 millimeters, a total width of substantially about 35 millimeters, and a total thickness of substantially about 19 millimeters.

[0095] The main body 60 of the inhalation device and / or system 50 is preferably sized to substantially about 40 millimeters long, substantially about 35 millimeters wide, and substantially about 19 millimeters thick.

[0096] The bottom portion 130 of the inhalation device and / or system 50 is preferably sized to substantially about 8 millimeters long, substantially about 35 millimeters wide, and substantially about 19 millimeters thick.

[0097] The top portion 70 of the inhalation device and / or system 50 is preferably sized to substantially about 12 millimeters long, substantially about 35 millimeters wide, and substantially about 19 millimeters thick. In reusable embodiments of the invention, the top portion 70 is preferably constructed from a metal material.

[0098] The bottom portion 130 is preferably shaped with one or two vent holes 132 (as perhaps best shown in FIGS. 3, 5, 7, and 18). An inside of the bottom portion 130 is accessible via two clamper devices which secure the bottom portion 130 to the main body 60 (as perhaps best shown in FIGS. 3, 7, 11, 13, and 39).

[0099] The top portion 70 is preferably shaped with one cutout 74 where the nasal or mouthpiece 76 fits tightly into (as perhaps best shown in FIGS. 11, 15, 17, 20-22, and 39). The nasal or mouthpiece 76 may preferably have a removable top cap 78 over it (as shown in FIG. 11) to preferably prevent evaporation when the device is not in use. An inside of the top portion 70 is accessible via a fishhook rim 72 which snaps into the main body 60, not meant for repeated attachment and removal.

[0100] The top portion 70 preferably has a wick and / or chamber switch 100 on it (as shown in FIGS. 15-18 and 20-23) which enables the user to select which wick 80a, 80b will be active for use. Preferably, the wick switch 100 prevents both wicks 80a, 80b from being active concurrently.

[0101] As aforesaid, in some preferred embodiments, the inside portion 62 of the main body 60 of the inhalation device and / or system 50 is provided with a substantially cylindrical shaped chamber compartment 64 (as perhaps best seen in FIG. 3) or two substantially cylindrical shapedchambers 64a, 64b (as perhaps best seen in FIG. 15). Preferably, the chambers 64, 64a, 64b extend downward with inner diameters of substantially about 12 millimeters, each. Within each chamber 64, 64a, 64b are preferably cone shaped clamper devices 66 which allow for a secure fit with the top portion 70, while providing free air flow (in the general direction of arrow “A”) through the main body 60. The cone shaped clamper devices 66 are preferably sized to be substantially about 12 millimeters wide and substantially about 4 millimeters long.

[0102] The wicks 80, 80a, 80b within the inhalation device and / or system 50 are preferably secured in place. Preferably, they may have (little or) no ability to move freely once the top portion 70 and / or the bottom portion 130 are fastened to the main body 60 (perhaps, as best shown in FIG. 3, 15, and 19-20). The wicks 80, 80a, 80b preferably do not touch side walls of the internal chambers 64, 64a, 64b, and are preferably pinched between top clamper devices 66 and bottom clamper devices 68.

[0103] As shown in FIGS. 13-18 (among others), other embodiments of the device may preferably be constructed for use with battery power systems. In these embodiments of the device, the chambers 64a, 64b in the main body 60 are preferably constructed out of ceramic material, and / or another material. Further, between the two chambers 64a, 64b is preferably a delivery cartridge. Battery-powered embodiments of the inhalation device and / or system 50 are preferably constructed to hold batteries with capacities as large as substantially about 1,800 milliampere hours, or only perhaps about 600 milliampere hours.

[0104] A user (not shown) preferably presses their nostril or mouth to the mouthpiece 76 to create a seal. The user may then proceed to inhale. Upon inhaling, one-way air valves 120 - e.g., adjacent to the bottom portion 130 - open to permit inhalation of the cannabis, nicotine, or medicinal compounds. Upon satisfaction, the user may then remove their nostril or mouth from the mouthpiece 76.

[0105] Some embodiments of the inhalation device and / or system 50 are preferably reusable and / or built for durability. The main body 60 is preferably constructed from a ceramic material. The ceramic preferably helps to prevent leaching and / or to keep the wick in a prime environment. Proper o-ring seals preferably help provide airtight seals to the ceramic main body 60.

[0106] The one-way valve 120 is preferably provided adjacent to the bottom portion 130. The mouth / nose piece 76 preferably helps to prevent the airflow “A” through the inhalation device and / or system 50 when not being used. This preferably helps prevent degradation of the active ingredients.

[0107] The inhalation device and / or system 50 is preferably the combination, as aforesaid, of the main body 60, the top portion 70, the bottom portion 130, the nasal or mouthpiece 76, and the two wicks 80a, 80b found in the interior chambers 64a, 64b of the main body 60.

[0108] In cannabis embodiments, the inhalation device and / or system 50 is preferably constructed to administer specific formulations (not shown) of cannabinoids, terpenes, and flavonoids, which may include but are not limited to: THC, THCa, THCv, CBD, CBDa, D8 THC, CBG, and / or CBN. Formulations having a relatively low viscosity may be preferred for some embodiments of the invention.

[0109] Wicks 80a, 80b may differ in shape and / or size, for example, to best align with the viscosity of the formulation and / or the intended dosage delivery rate. Each of the wick cartridges 80a, 80b preferably holds about 1 to 4 mL of the formulation, and perhaps even about 20 mL of the formulation in some variations. Densities of the wick cartridges 80a, 80b are preferably about 0.02 to 0.31 g / cubic centimeter ±10%. The wick cartridges 80a, 80b are preferably constructed from a cotton material.

[0110] A general base formulation may preferably be provided according to the invention. The general base formulation may preferably include one or more components, as follow: (A) a carrier (e.g., menthol) which may preferably range from substantially about 20% to substantially about 40% by weight; (B) a sub-carrier (e.g., squalane, Miglyol 812, Fluidity 2.0) which may preferably range from substantially about 15% to substantially about 40% by weight; (C) one or more cannabinoids, preferably processed to an average of about 0.1 to 15 microns and / or no greater than about 20 microns, and more preferably processed to an average of about 0.1 to 5 microns and / or no greater than about 10 microns, and still more preferably processed to an average of about 0.1 to 2 microns and / or no greater than about 5 microns, (e.g., CBD, CBDA, CBG, CBN, THC) which may preferably range from substantially about 5% to substantially about 40% by weight; (D) an emulsifier (e.g., Sunflower Lecithin) which may preferably range from substantially about 0.4% to substantially about 6% by weight; (E) a surfactant (e.g., Tween 80) which may preferably range from substantially about 0.1% to substantially about 3% by weight; (F) a stabilizer (e.g., a cellulose derivative) which may preferably range from substantially about 0.1% to substantially about 3% by weight; (G) an Abies Sibirica oil which may preferably range from substantially about 0.01% to substantially about 5% by weight; and / or (H) a methyl salicylate which may preferably range from substantially about 0.01% to substantially about 4% by weight.

[0111] In addition or instead, a daytime base formulation may preferably be provided according to the invention. The daytime base formulation may preferably include one or more components, as follow: (A) a carrier (e.g., menthol) which may preferably range from substantially about 20% to substantially about 40% by weight; (B) a sub-carrier (e.g., camphor, tea tree) which may preferably range from substantially about 15% to substantially about 40% by weight; (C) a daytime terpene profde which may preferably range from substantially about 5% to substantially about 15% by weight; (D) one or more cannabinoids, preferably processed to an average of about 0.1 to 15microns and / or no greater than about 20 microns, and more preferably processed to an average of about 0.1 to 5 microns and / or no greater than about 10 microns, and still more preferably processed to an average of about 0. 1 to 2 microns and / or no greater than about 5 microns, (e.g., CBD, CBDA, CBG, CBN, THC) which may preferably range from substantially about 5% to substantially about 40% by weight; (E) an emulsifier (e.g., Sunflower Lecithin) which may preferably range from substantially about 0.4% to substantially about 6% by weight; (F) a surfactant (e.g., Tween 80) which may preferably range from substantially about 0.1% to substantially about 3% by weight; (G) a stabilizer (e.g., a cellulose derivative) which may preferably range from substantially about 0.1% to substantially about 3% by weight; (H) an Abies Sibirica oil which may preferably range from substantially about 0.01% to substantially about 5% by weight; and / or (I) a methyl salicylate which may preferably range from substantially about 0.01% to substantially about 4% by weight. The daytime terpene profde may preferably comprise one or more of the following: (i) a limonene which may preferably range from substantially about 5% to substantially about 55% by weight; (ii) a delta-3 camene which may preferably range from substantially about 5% to substantially about 55% by weight; and / or (iii) a myrcene which may preferably range from substantially about 5% to substantially about 55% by weight.

[0112] In addition or instead, a night time base formulation may preferably be provided according to the invention. The night time base formulation may preferably include one or more components, as follow: (A) a carrier (e.g., menthol) which may preferably range from substantially about 20% to substantially about 40% by weight; (B) a sub-carrier (e.g., camphor, tea tree) which may preferably range from substantially about 15% to substantially about 40% by weight; (C) a night time terpene profde which may preferably range from substantially about 5% to substantially about 15% by weight; (D) one or more cannabinoids, preferably processed to an average of about 0.1 to 15 microns and / or no greater than about 20 microns, and more preferably processed to an average of about 0.1 to 5 microns and / or no greater than about 10 microns, and still more preferably processed to an average of about 0.1 to 2 microns and / or no greater than about 5 microns, (e.g., CBD, CBDA, CBG, CBN, THC) which may preferably range from substantially about 5% to substantially about 40% by weight; (E) an emulsifier (e.g., Sunflower Lecithin) which may preferably range from substantially about 0.4% to substantially about 6% by weight; (F) a surfactant (e.g., Tween 80) which may preferably range from substantially about 0.1% to substantially about 3% by weight; (G) a stabilizer (e.g., a cellulose derivative) which may preferably range from substantially about 0.1% to substantially about 3% by weight; (H) an Abies Sibirica oil which may preferably range from substantially about 0.01% to substantially about 5% by weight; and / or (I) a methyl salicylate which may preferably range from substantially about 0.01% to substantially about 4% by weight. The night time terpene profde may preferably compriseone or more of the following: (i) a linalool which may preferably range from substantially about 5% to substantially about 55% by weight; (ii) a terpinolene which may preferably range from substantially about 5% to substantially about 55% by weight; and / or (iii) a caryophyllene which may preferably range from substantially about 5% to substantially about 55% by weight.

[0113] In addition or instead, an epilepsy cannabinoid medication formulation may preferably be provided according to the invention. The epilepsy cannabinoid medication formulation may preferably include one or more components, as follow: (A) a carrier (e.g., menthol) which may preferably range from substantially about 20% to substantially about 40% by weight; (B) one or more cannabinoids, preferably processed to an average of about 0.1 to 15 microns and / or no greater than about 20 microns, and more preferably processed to an average of about 0.1 to 5 microns and / or no greater than about 10 microns, and still more preferably processed to an average of about 0.1 to 2 microns and / or no greater than about 5 microns, (e.g., CBD, CBDA, CBDV, CBG, CBN, THC) which may preferably amount to substantially about 5 mg of active dose per inhale, with substantially about 300 mg contained in a 3-day vessel that may be provided according to the invention; (C) a limonene which may preferably amount to substantially about 1 mg of active dose per inhale, with substantially about 15 mg contained in a 3-day vessel that may be provided according to the invention; (D) a myrcene which may preferably amount to substantially about 1 mg of active dose per inhale, with substantially about 15 mg contained in a 3-day vessel that may be provided according to the invention; (E) an emulsifier (e.g., Sunflower Lecithin) which may preferably range from substantially about 0.4% to substantially about 6% by weight; (F) a surfactant (e.g., Tween 80) which may preferably range from substantially about 0.1% to substantially about 3% by weight; (G) a stabilizer (e.g., a cellulose derivative) which may preferably range from substantially about 0.1% to substantially about 3% by weight; (H) an Abies Sibirica oil which may preferably range from substantially about 0.01% to substantially about 5% by weight; and / or (I) a methyl salicylate which may preferably range from substantially about 0.01% to substantially about 4% by weight. The epilepsy cannabinoid medication formulation may preferably, in addition or instead, include one or more additional components, as follow: (J) Curcuma longa, preferably to help reduce neuroinflammation and / or oxidative stress (which may be implicated in seizure disorders), which may preferably amount to substantially about 1.5 mg of active dose per inhale, with substantially about 22.5 mg contained in a 3-day vessel that may be provided according to the invention; and / or (K) Vitamin B6, preferably to help in neurotransmitter synthesis, help regulate brain function, and / or help reduce seizure frequency, which may preferably amount to substantially about 0.65 mg of active dose per inhale, with substantially about 9.75 mg contained in a 3-day vessel that may be provided according to the invention. The epilepsy cannabinoid medication formulation may in addition or instead include (L) ethanol, if necessary ordesired. In some embodiments, the epilepsy cannabinoid medication formulation may, in addition or instead, include (M) a sub-carrier (e.g., camphor) which - in such case - may preferably range from substantially about 15% to substantially about 40% by weight.

[0114] For one or more of the formulations described herein, menthol may have been listed as an example carrier, but other carriers are also encompassed by the present invention, especially any which may help to open nasal passages, may act as a nasal decongestant (e.g., mild nasal decongestants), may help make it easier to breathe through the nose, and / or may facilitate delivery of inhalants. Herein, camphor may have been listed as an example sub-carrier, but other sub-carriers are also encompassed by the present invention, especially any which may facilitate easier breathing and / or improve delivery of inhalants. In fact, the present invention may preferably be broad enough to encompass the use of any possible volatile carriers and sub-carriers in place of the carriers and sub-carriers that are expressly disclosed and taught herein.

[0115] In some formulations described herein, limonene may be listed as an included compound, but other compounds may take its place in other formulations that fall within the scope of the invention, especially any which may help prevent appetite suppression effects (e.g., from CBD), may enhance therapeutic effects (e.g., of cannabinoids), may have one or more anticonvulsant properties, and / or may help mitigate somnolence and / or sedation (e.g., including lethargy). Likewise, myrcene may be listed as an included compound in some formulations described herein, but other compounds may take its place in other formulations that fall within the scope of the invention, especially any which may enhance therapeutic effects (e.g., of cannabinoids) and / or may have one or more anticonvulsant properties.

[0116] Some embodiments of the invention are preferably wickless and have a heated internal chamber 64 (as perhaps best seen in FIGS. 9, 14, 18, and 28) for maximum volatility. An activation button 110 releases flow cut-off members 112 and allows free air flow “A” of the formulation to venturi powered nozzles. The activation button 110 preferably also preheats the chamber 64 and maintains its heat while the user is inhaling. The nozzles release the formulations in tiny drops that only flow when the user breathes in through the device. The cartridge 80 may be provided in the form of a tank for the formulation that is gently pressurized, mechanically and / or with a gas. Alternately, the cartridge 80 may be provided in the form of a syringe-style tank, which preferably allows for a mechanically-driven click twist. In either case, the cartridge 80 preferably does not allow air to fdl any empty space in the cartridge 80, thus preventing oxidation and degradation of the active ingredients.

[0117] Preferably, the invention helps provide one or more advantages over the prior art - and / or helps to solve, obviate, and / or mitigate one or more problems associated with the prior art - including (but not limited to) those described below and / or elsewhere herein.

[0118] As detailed herein, the invention preferably provides one or more of the following: (A) the noncombustible administration of cannabis and / or nicotine preferably obviates the notable scent association with smoking the same. (B) The invention’s material composition preferably allows for reuse and recycling, reducing the number of pollutants which might otherwise enter landfills. (C) The noncombustible administration of cannabis and / or nicotine preferably reduces the number of harmful byproducts inhaled by the consumer. And / or, (D) the noncombustible inhalation method of consumption preferably effectively mimics the feeling of smoking cannabis and / or nicotine while limiting the harmful effects of doing so. Preferably, there are low costs associated with manufacturing the invention. As such, the inhalation device is preferably well-adapted to enter the marketplace in a cost-effective manner for both manufacturers and consumers.

[0119] The invention is contemplated for use by or in association with inhalation devices, including cannabis and / or nicotine inhalation devices, as described herein. The invention, however, is not so limited. And, in any event, other embodiments, which fall within the scope of the invention, may be provided. For example, FIGS. 13 to 18 depict embodiments of the invention which are adapted for use with battery systems.

[0120] For example, in another embodiment which falls within the scope of the invention, oil based formulations may be used. For example, a daytime base formulation may preferably include one or more of the following components: (A) a menthol which may preferably range from substantially about 20% to substantially about 40% by weight; (B) a carrier (e.g., squalane, Miglyol 812, Fluidity 2.0) which may preferably range from substantially about 20% to substantially about 50% by weight; (C) one or more cannabinoids which may preferably range from substantially about 20% to substantially about 60% by weight; (D) one or more terpenes (e.g., Limonene 2-8%, Mycrene 2-8%, and / or Caryophollene 2-8% alpha or beta) which may preferably range from substantially about 5% to substantially about 15% by weight; and / or (E) one or more flavorants which may preferably range from substantially about 1% to substantially about 10% by weight.

[0121] Similarly, a night time base formulation may preferably include one or more of the following components: (A) a menthol which may preferably range from substantially about 20% to substantially about 40% by weight; (B) a carrier (e.g., squalane, Miglyol 812, Fluidity 2.0) which may preferably range from substantially about 20% to substantially about 50% by weight; (C) one or more cannabinoids which may preferably range from substantially about 20% to substantially about 60% by weight; (D) one or more terpenes (e.g., Linalool 2-8%, Mycrene 2-8%, and / or Caryophollene 2-8% alpha or beta) which may preferably range from substantially about 5% to substantially about 15% by weight; and / or (E) one or more flavorants which may preferably range from substantially about 1% to substantially about 10% by weight.

[0122] In another example embodiment, which falls within the scope of the invention, “high octane” base formulations may preferably include one or more of the following components: (A) a menthol which may preferably range from substantially about 20% to substantially about 40% by weight; (B) a carrier (e.g., squalane, Miglyol 812, Fluidity 2.0) which may preferably range from substantially about 20% to substantially about 50% by weight; (C) one or more cannabinoids (e.g., THC 2-20%, CBD 2-5%, THCV 2-10%, CBG 2-6%, and / or CBC 2-6%) which may preferably range from substantially about 20% to substantially about 60% by weight; (D) one or more terpenes (e.g., Limonene 2-8%, beta-pinene 2-6%, Caryophollene 2-6% alpha or beta, Sabinene 1-4% and / or Eucolyptol 1-4%) which may preferably range from substantially about 5% to substantially about 15% by weight; and / or (E) one or more flavorants which may preferably range from substantially about 1% to substantially about 10% by weight. Some variations of the “high octane” formulations may preferably, but need not necessarily, in addition or instead include one or more of the following components: (F) B12 1-3% (e.g., Cobalamin); (G) B6 1-3% (e.g., Pyridoxine); (H) B5 1-3% (e.g., Pantothenic Acid), (I) Bl 1-3% (e.g., Thiamine); (J) B2 1-3% (e.g., Riboflavin); (K) B3 1-3% (e.g., Niacin); (L) Rhodiola Rosea Extract 3% - 10%; (M) L-Theanine 2-10%; and / or (N) Caffeine 2-6%.

[0123] In a further embodiment that falls within the scope of the invention, another epilepsy or “EPICANN” formulation may be provided, as an oil-in-oil emulsion base formulation, which may preferably include one or more of the following components: (A) a menthol which may preferably range from substantially about 20% to substantially about 40% by weight; (B) a carrier (e.g., squalane, Miglyol 812, Fluidity 2.0) which may preferably range from substantially about 20% to substantially about 50% by weight; (C) one or more cannabinoids (e.g., THC 2-20%, CBD 2-5%, CBG 2-6%, and / or CBDV 2-6%) which may preferably range from substantially about 20% to substantially about 60% by weight; (D) one or more terpene materials (e.g., Limonene 2-8%, Myrcene 2-6%, Caryophollene 2-6% alpha or beta, Curcuma Longa 0.1-3%, and / or Eucolyptol 1-4%) which may preferably range from substantially about 5% to substantially about 15% by weight; (E) one or more flavorants which may preferably range from substantially about 1% to substantially about 10% by weight; and / or (F) B6 1-3% (e.g., Pyridoxine).

[0124] In yet another embodiment that falls within the scope of the invention, a “PTSD” formulation may be provided, as an oil-in-oil emulsion base formulation, which may preferably include one or more of the following components: (A) a menthol which may preferably range from substantially about 20% to substantially about 40% by weight; (B) a carrier (e.g., squalane, Miglyol 812, Fluidity 2.0) which may preferably range from substantially about 20% to substantially about 50% by weight; (C) one or more cannabinoids (e.g., THC 1-4%, CBD 2-15%, CBG 2-15%, and / or CBN 2-15%) which may preferably range from substantially about 20% to substantially about 60%by weight; (D) one or more terpene materials (e.g., Linalool 2-6%, Limonene 2-8%, Myrcene 2-6%, and / or Caryophollene 2-6% alpha or beta) which may preferably range from substantially about 5% to substantially about 15% by weight; (E) one or more flavorants which may preferably range from substantially about 1% to substantially about 10% by weight; (F) Ashwanda which may preferably be in the range of about 1-5% by weight; (G) Rhodiola Rosea Extract which may preferably be in the range of about 1-3% by weight; and / or (H) L-Theanine which may preferably be in the range of about 1-3% by weight.

[0125] In a yet further embodiment that falls within the scope of the invention, a trauma pain-control and / or military / emergency response formulation may be provided, as an oil-in-oil emulsion base formulation, which may preferably include one or more of the following components: (A) a menthol which may preferably range from substantially about 20% to substantially about 40% by weight; (B) a carrier (e.g., squalane, Miglyol 812, Fluidity 2.0) which may preferably range from substantially about 20% to substantially about 50% by weight; (C) one or more cannabinoids (e.g., THC 4-10%, CBD 2-22%, and / or CBN 2-15%) which may preferably range from substantially about 20% to substantially about 60% by weight; (D) one or more terpene materials (e.g., Linalool 2-6%, Pinene 2-8%, Myrcene 2-6%, Caryophollene 2-6% alpha or beta, and / or Alpha-Bisabolol 1-5%) which may preferably range from substantially about 5% to substantially about 15% by weight; (E) one or more flavorants which may preferably range from substantially about 1% to substantially about 10% by weight; (F) Fentanyl which may preferably be in the range of about 2-10% by weight; (G) morphine which may preferably be in the range of about 2-10% by weight; (H) Rhodiola Rosea Extract which may preferably be in the range of about 1-3% by weight; (I) L-Theanine which may preferably be in the range of about 1-3% by weight; and / or (J) Lidocaine which may preferably be in the range of about 1-3% by weight.

[0126] The device, system, and / or method according to the invention preferably helps deliver and / or position one or more cannabinoids and / or nicotine through a process that may preferably include one or more of the following: transcellular diffusion; para cellular transport; vesicle mediated transport; and / or carrier mediated transport.

[0127] Future improvements or modifications to the idea may include (among other things) further adaptations for the inhalation of nicotine and / or medicinal compounds. In addition or instead, some embodiments of the invention may provide for a warming feature to warm one or more internal chambers, preferably, without coming into direct contact with the carrier vessel or the wick or cartridge component.

[0128] In addition or instead, some embodiments of the invention may provide dosage and / or usage tracking functionality, preferably including lung pressure data from the device, for example, for patient and / or doctor monitoring (e.g., via Bluetooth).

[0129] The foregoing description has been presented for the purpose of illustration and is not intended to be exhaustive or to limit the invention to the precise form disclosed.

[0130] Naturally, in view of the teachings and disclosures herein, persons having ordinary skill in the art may appreciate that alternate designs and / or embodiments of the invention may be possible (e.g, with substitution of one or more components for others, with alternate configurations of components, etc). Although some of the components, relations, configurations and / or steps according to the invention are not specifically referenced in association with one another, they may be used, and / or adapted for use, in association therewith. All of the aforementioned and various other structures, configurations, relationships, utilities, any which may be depicted and / or based hereon, and the like may be, but are not necessarily, incorporated into and / or achieved by the invention. Any one or more of the aforementioned structures, configurations, relationships, utilities and the like may be implemented in and / or by the invention, on their own, and / or without reference, regard or likewise implementation of any of the other aforementioned structures, configurations, relationships, utilities and the like, in various permutations and combinations, as will be readily apparent to those skilled in the art, without departing from the pith, marrow, and spirit of the disclosed invention.

[0131] Other modifications and alterations may be used in the design, manufacture, and / or implementation of other embodiments according to the present invention without departing from the spirit and scope of the invention, which is limited only by the claims of this patent application.

Claims

CLAIMS1. An inhalation system for passive, non-combustible inhalation and administration of cannabinoids, nicotine, and medicinal compounds, wherein the inhalation system comprises:(a) a main vessel body that has an inside portion which defines one or more internal chambers;(b) a top portion that securely engages the main vessel body, covers the internal chambers, and is shaped to define one or more inhalation holes therethrough for passage of an air flow from the internal chambers upon inhalation by a user;(c) one or more cartridges secured within the internal chambers; and(d) a formulation contained within the cartridges; wherein the formulation comprises one or more active ingredients, and particulates of the active ingredients are passively and non-combustibly released from the cartridges, and entrained within said air flow, upon said inhalation by the user; wherein the particulates are sized for absorption into the bloodstream via lung tissue and / or nasal mucosa of the user; and wherein the active ingredients are selected from the group consisting of cannabis, nicotine, and medicinal compounds.

2. The inhalation system according to claim 1, wherein the formulation further comprises one or more terpenoids; and wherein the aforesaid release of the particulates from the cartridges occurs via passive aerosolization of the terpenoids.

3. The inhalation system according to claim 2, wherein the terpenoids comprise one or more monoterpenoids.

4. The inhalation system according to claim 2, wherein the terpenoids comprise one or more members selected from the group consisting of menthol, eucalyptol, camphor, and tea tree oil.

5. The inhalation system according to claim 2, wherein the terpenoids are vasodilating and selected from the group consisting of beta caryophelle, linalool, alpha pinene, and myrcene.

6. The inhalation system according to claim 2, wherein the terpenoids comprise one or more members selected from the group consisting of volatile carriers and permeation enhancers.

7. The inhalation system according to any one of claims 1 to 6, wherein said one or more internal chambers comprise two internal chambers, and said one or more cartridges comprise two cartridges; and wherein each of said cartridges is secured within a respective one of said internal chambers.

8. The inhalation system according to claim 7, further comprising a switch that is manually actuable by the user to select one of the cartridges for active use.

9. The inhalation system according to any one of claims 1 to 8, wherein the main vessel body is reusable and constructed from one or more ceramic materials.

10. The inhalation system according to any one of claims 1 to 8, wherein the main vessel body is disposable and constructed from one or more plastic materials.

11. The inhalation system according to any one of claims 1 to 10, wherein the top portion is rounded to sealably conform with the shape of a mouth or nostril of the user.

12. The inhalation system according to one of claims 1 to 10, wherein the top portion comprises a nose- / mouthpiece to sealably conform with the shape of a nostril or mouth of the user.

13. The inhalation system according to claim 12, wherein the nose- / mouthpiece is constructed from a silicone material.

14. The inhalation system according to one of claims 1 to 13, wherein the top portion is selectively twistable to move the inhalation holes between (i) a closed configuration which blocks the inhalation holes in the top portion against said air flow, and thus limits the aforesaid passive release of the particulates, and (ii) an open configuration which permits said air flow and the aforesaid passive release of the particulates.

15. The inhalation system according to one of claims 1 to 13, further comprising a selectively removable top cap that (i) securely engages the top portion, blocks the inhalation holes in the top portion against said air flow, and thus limits the aforesaid passive release of the particulates, and (ii) when removed, permits said air flow and the aforesaid passive release of the particulates.

16. The inhalation system according to any one of claims 1 to 15, wherein the top portion has a fishhook rim that snaps onto the main vessel body.

17. The inhalation system according to any one of claims 1 to 16, wherein the cartridges are wick cartridges.

18. The inhalation system according to claim 17, wherein each of the wick cartridges holds about 1 to 20 mL of the formulation.

19. The inhalation system according to claim 17, wherein each of the wick cartridges holds a formulation density of about 0.02 to 0.31 g / cubic centimeter ± about 10%.

20. The inhalation system according to any one of claims 1 to 19, wherein the wick cartridges are constructed from a cotton material.

21. The inhalation system according to any one of claims 1 to 16, further comprising an activation button that is selectively actuable to heat the internal chambers and the cartridges, and to permit the aforesaid passage of said air flow from the internal chambers out through the inhalation holes upon inhalation by the user; and further comprising one or more flow cut-off members that block the aforesaid passage of said air flow from the internal chambers when the activation button is not actuated.

22. The inhalation system according to any one of claims 1 to 21, further comprising top and bottom clamper devices within the internal chambers; wherein the top and bottom clamper devices secure the cartridges within the internal chambers.

23. The inhalation system according to any one of claims 1 to 22, further comprising a one-way valve to permit said air flow over the cartridges and out through the inhalation holes in the top portion upon inhalation by the user, and to otherwise block said air flow.

24. The inhalation system according to claim 23, wherein the one-way valve is closed at all times other than upon inhalation by the user.

25. The inhalation system according to any one of claims 1 to 24, wherein each of the particulates has a size of less than about ten microns (10 pm).

26. The inhalation system according to claim 25, wherein each of the particulates has a size of less than about five microns (5 pm).

27. The inhalation system according to any one of claims 1 to 26, wherein the formulation further comprises one or more emulsifying and / or dispersing agents.

28. The inhalation system according to any one of claims 1 to 27, further comprising a bottom portion that securely engages the main vessel body, covers the internal chambers, and is shaped to define one or more ventilation holes therethrough for passage of said air flow into the internal chambers upon inhalation by the user.

29. The inhalation system according to any one of claims 1 to 28, wherein the active ingredients comprise one or more members selected from the group consisting of THC, THCa, THCv, CBD, CBDa, D8 THC, CBG, and CBN; and wherein the formulation further comprises one or more terpenes and / or flavonoids.

30. The inhalation system according to any one of claims 1 to 29, wherein the main vessel body is pocket-sized for user convenience and portability.

31. A cannabinoid formulation for non-combustible inhalation, comprising:(a) one or more cannabinoids selected from the group consisting of THC, THCa, THCv, CBD, CBDa, D8 THC, CBG, and CBN;(b) one or more emulsifying and / or dispersing agents selected from the group consisting of lecithin, sorbitan trioleate, Span 80, and Tween 85; and(c) a volatile carrier oil comprising menthol and / or another monoterpenoid.

32. The cannabinoid formulation according to claim 31, wherein the cannabinoids are an appropriate size to enter the bloodstream via nasal mucosa and / or for absorption in lung tissue.

33. The cannabinoid formulation according to claim 32, wherein the emulsifying and / or dispersing agents achieve particle sizes less than about ten microns (10 pm).

34. The cannabinoid formulation according to claim 33, wherein the emulsifying and / or dispersing agents achieve particle sizes less than about five microns (5 pm).

Images